Enanta Pharmaceuticals, Inc.
ENTADrugs in Pipeline
6
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
EDP-938
Respiratory Syncytial Virus
EDP-938 Dose 1
RSV Infection
EDP-235
COVID-19
EDP-305 1 mg
Primary Biliary Cholangitis
EDP-305 Dose 1
Non-Alcoholic Steatohepatitis
EDP-323 Dose Regimen 1
RSV Infection
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EDP-938 | Phase 2 | Respiratory Syncytial Virus | - | - |
EDP-938 Dose 1 | Phase 2 | RSV Infection | - | - |
EDP-235 | Phase 2 | COVID-19 | - | - |
EDP-305 1 mg | Phase 2 | Primary Biliary Cholangitis | - | - |
EDP-305 Dose 1 | Phase 2 | Non-Alcoholic Steatohepatitis | - | - |
EDP-323 Dose Regimen 1 | Phase 2 | RSV Infection | - | - |
RSV Infection
2 drugs in this indication
Respiratory Syncytial Virus
1 drug in this indication
COVID-19
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
Non-Alcoholic Steatohepatitis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Enanta Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in Enanta Pharmaceuticals, Inc.'s (ENTA) pipeline across Phase 2. Its lead program is EDP-938 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Enanta Pharmaceuticals, Inc.'s next FDA catalyst?→
Enanta Pharmaceuticals, Inc.'s (ENTA) next tracked catalyst is a Earnings expected November 16, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track ENTA biotech catalysts?→
Add ENTA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Enanta Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.